Skip to main content

Table 3 Clinical Study Duration

From: Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

  Eptinezumab 100 mg Eptinezumab 300 mg Eptinezumab 1000 mg Placebo
N = 701 N = 695 N = 81 N = 791
Total Time in Clinical Study, n (%)
  ≥12 weeks 680 (97.0) 681 (98.0) 78 (96.3) 766 (96.8)
  ≥24 weeks 642 (91.6) 649 (93.4) 46 (56.8) 692 (87.5)
  ≥36 weeks 288 (41.1) 293 (42.2) N/A 280 (35.4)
  ≥48 weeks 263 (37.5) 270 (38.8) N/A 256 (32.4)
  1. Total Exposure Time = Last day on study – first dose date + 1. N/A Not applicable